Esther I. Verhoef

Esther I. Verhoef

Auto-generated profile, based on publicly available information

Esther I. Verhoef

Department of Pathology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
CKCharlotte F Kweldam
Charlotte F Kweldam
IKIntan P Kümmerlin
Intan P Kümmerlin
DNDaan Nieboer
Daan Nieboer
EVEsther I Verhoef
Esther I Verhoef
ESEwout W Steyerberg
Ewout W Steyerberg
GLGeert J van Leenders
Geert J van Leenders

1 November 2017 in European Urology
Verified
Journal Article
Closed access
MCMelvin LK Chua
Melvin LK Chua
WLWinnie Lo
Winnie Lo
MPMelania Pintilie
Melania Pintilie
JMJure Murgic
Jure Murgic
ELEmilie Lalonde
Emilie Lalonde
RBRobert G. Bristow
Robert G. Bristow

22 October 2018 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
EHEva Hollemans
Eva Hollemans
EVEsther I. Verhoef
Esther I. Verhoef
CBChris H. Bangma
Chris H. Bangma
JRJohn Rietbergen
John Rietbergen
JHJozien Helleman
Jozien Helleman
GLGeert J.L.H. van Leenders
Geert J.L.H. van Leenders
Invasive cribriform and intraductal carcinoma are associated with adverse clinical outcome in patients with Gleason score 7 prostate cancer. It is yet unclear whether invasive cribriform and intraductal carcinoma of the prostate both have independent prognostic value, or whether field size of invasive cribriform carcinoma has impact on disease outcome. Our objective was to determine the prognostic impact of intraductal and invasive cribriform prostate cancer histological subtypes in radical prostatectomies. We reviewed 420 prostatectomy specimens with ISUP grade 2 prostate cancer, assessed the percentages of Gleason grade 4 and tertiary 5, and performed immunohistochemistry for basal cells to discriminate intraductal from invasive cribriform growth. Small and large invasive cribriform fields were distinguished based on a diameter of at least twice the size of adjacent pre-existent normal glands. Clinicopathological parameters and biochemical recurrence-free survival were used as endpoints. Cribriform architecture was observed in 228 (54.3%) men, 103 (24.5%) of whom had intraductal, 194 (46.2%) small invasive, and 34 (8.1%) large invasive cribriform growth. Large invasive cribriform architecture was associated with older age (P < 0.001), higher percentage Gleason grade 4 (P = 0.001), extraprostatic expansion (P < 0.001), and more frequent lymph node metastases (P = 0.002), when compared with small invasive cribriform and/or intraductal carcinoma. Univariate analysis identified PSA, pT-stage, surgical margin status, and intraductal and invasive cribriform growth as significant predictors for biochemical recurrence-free survival. In multivariable Cox regression analysis, pT-stage (hazard ratio = 1.64, 95% CI: 1.02–2.63, P = 0.04), positive surgical margins (hazard ratio = 3.28, 95% CI: 2.06–5.23, P < 0.001), and large cribriform growth (hazard ratio = 4.36, 95% CI: 2.08–9.17, P < 0.001) were independent predictors for biochemical recurrence-free survival, while intraductal carcinoma, small cribriform growth, and percentage of Gleason grade 4 were not. In conclusion, large cribriform fields represent an aggressive subpattern of invasive cribriform prostate cancer and are an independent predictive factor for biochemical recurrence-free survival in ISUP grade 2 prostate cancer patients.

1 February 2020 in European Urology
Verified
Journal Article
Closed access
GLGeert J.L.H. van Leenders
Geert J.L.H. van Leenders
CKCharlotte F. Kweldam
Charlotte F. Kweldam
EHEva Hollemans
Eva Hollemans
IKIntan P. Kümmerlin
Intan P. Kümmerlin
DNDaan Nieboer
Daan Nieboer
Monique RoobolMonique Roobol
Monique Roobol

21 September 2016 in Histopathology
Verified
Journal Article
Closed access
PDF file
MRMartin Van Royen
Martin Van Royen
EVEsther I Verhoef
Esther I Verhoef
CKCharlotte F. Kweldam
Charlotte F. Kweldam
WCWiggert A van Cappellen
Wiggert A van Cappellen
GKGert‐Jan Kremers
Gert‐Jan Kremers
GLGeert J.L.H. van Leenders
Geert J.L.H. van Leenders

1 January 2015 in Cancer Research
Verified
Journal Article
Open access
PDF file
VGVeerander P.S. Ghotra
Veerander P.S. Ghotra
SHShuning He
Shuning He
GHGeertje van der Horst
Geertje van der Horst
SNSteffen Nijhoff
Steffen Nijhoff
HBHans de Bont
Hans de Bont
EDErik H.J. Danen
Erik H.J. Danen
Improved targeted therapies are needed to combat metastatic prostate cancer. Here, we report the identification of the spleen kinase SYK as a mediator of metastatic dissemination in zebrafish and mouse xenograft models of human prostate cancer. Although SYK has not been implicated previously in this disease, we found that its expression is upregulated in human prostate cancers and associated with malignant progression. RNAi-mediated silencing prevented invasive outgrowth in vitro and bone colonization in vivo, effects that were reversed by wild-type but not kinase-dead SYK expression. In the absence of SYK expression, cell surface levels of the progression-associated adhesion receptors integrin α2β1 and CD44 were diminished. RNAi-mediated silencing of α2β1 phenocopied SYK depletion in vitro and in vivo, suggesting an effector role for α2β1 in this setting. Notably, pharmacologic inhibitors of SYK kinase currently in phase I–II trials for other indications interfered similarly with the invasive growth and dissemination of prostate cancer cells. Our findings offer a mechanistic rationale to reposition SYK kinase inhibitors for evaluation in patients with metastatic prostate cancer. Cancer Res; 75(1); 230–40. ©2014 AACR.